Literature DB >> 15112277

P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.

Jacek Jassem1, Ewa Jassem, Joanna Jakóbkiewicz-Banecka, Witold Rzyman, Andrzej Badzio, Rafał Dziadziuszko, Grazyna Kobierska-Gulida, Amelia Szymanowska, Marcin Skrzypski, Maciej Zylicz.   

Abstract

BACKGROUND: The objective of the current study was to determine whether tumor cells harboring P53 and K-ras mutations could be detected in histopathologically tumor-free surgical margins in patients with nonsmall cell lung carcinoma who underwent complete pulmonary resection.
METHODS: In 118 consecutive patients, DNA obtained from primary tumors and from surgical margins was extracted for molecular analysis. A fragment of P53 gene encompassing exons 5-8 and codon 12 of the K-ras gene were amplified with the polymerase chain reaction technique and were assayed for the presence of mutations.
RESULTS: P53 and K-ras mutations were found in 30% and 39% of primary tumors, respectively, and in 11 (9%) and 22 (18%) apparently tumor-free surgical margins, respectively. At least 1 of those mutations was found in surgical margins in 29 patients (25%), and both mutations were found in 2 patients (1.7%). P53 mutations in surgical margins accompanied mutations in primary tumors in 9 of 35 patients (26%), and K-ras mutations accompanied mutations in primary tumors in 20 of 46 patients (44%). Among patients with either mutation in primary tumors, the incidence of at least 1 mutation in surgical margins was 43% (28 of 65 patients). In four patients, mutations (two K-ras mutations and two P53 mutations) were found in surgical margins despite the absence of the corresponding mutations in primary tumors. The presence of mutations in primary tumors and in surgical margins was not related significantly to clinical characteristics or to patient outcomes.
CONCLUSIONS: P53 and K-ras mutations are frequent events in surgical margins determined to be tumor free on light microscopy. The clinical relevance of these findings remains to be established. Copyright 2004 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15112277     DOI: 10.1002/cncr.20191

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Molecular Analysis of Oncogenic Mutations in Resected Margins by Next-Generation Sequencing Predicts Relapse in Non-Small Cell Lung Cancer Patients.

Authors:  Weitian Wei; Xingliang Li; Mengmeng Song; Changchun Wang
Journal:  Onco Targets Ther       Date:  2020-09-25       Impact factor: 4.147

2.  Molecular chaperones in the acquisition of cancer cell chemoresistance with mutated TP53 and MDM2 up-regulation.

Authors:  Zuzanna Tracz-Gaszewska; Marta Klimczak; Przemyslaw Biecek; Marcin Herok; Marcin Kosinski; Maciej B Olszewski; Patrycja Czerwińska; Milena Wiech; Maciej Wiznerowicz; Alicja Zylicz; Maciej Zylicz; Bartosz Wawrzynow
Journal:  Oncotarget       Date:  2017-06-30

3.  Detection of oncogenic mutations in resected bronchial margins by next-generation sequencing indicates early relapse in stage IA lung adenocarcinoma patients.

Authors:  Tangfeng Lv; Jiawei Zou; Hongbing Liu; Qin Shen; Zhenfeng Lu; XiaoJun Zhou; Xiaonan Wang; Yong Song
Journal:  Oncotarget       Date:  2017-06-20

4.  Targeted next-generation sequencing reveals recurrence-associated genomic alterations in early-stage non-small cell lung cancer.

Authors:  William C S Cho; Kien Thiam Tan; Victor W S Ma; Jacky Y C Li; Roger K C Ngan; Wah Cheuk; Timothy T C Yip; Yi-Ting Yang; Shu-Jen Chen
Journal:  Oncotarget       Date:  2018-11-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.